AP 144 - Alphageneron Pharmaceuticals
Alternative Names: Allogeneic donor genetically edited NK cell therapy; Allogeneic natural killer cell therapy - Alphageneron Pharmaceuticals; ANKASTIM; AP-144 - Alphageneron PharmaceuticalsLatest Information Update: 28 Sep 2025
At a glance
- Originator Alphageneron Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Glioblastoma in USA (IV)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (IV)